The Swiss group shells out $2bn for Synnovation’s mutation-selective PI3Kα inhibitor.
ApexOnco Front Page
Recent articles
A unique VEGF trispecific and mRNA-based T-cell engager will also be featured at the congress.
Varegacestat’s pivotal study reads out imminently.
The group will take HRS-4642 into a Chinese phase 3 in first-line pancreatic cancer.
The pivotal Harmoni-GI3 study has started enrolling patients.
ASH and SABCS approach.
Readout of the Preserve-003 trial in post-PD-(L)1 NSCLC is due in December.
New first-in-human trials include Kivu and Menarini projects acting on PKT7 and KIF18A.
